Order by 12pm EST Mon–Fri. Free U.S. shipping over $99.
Third-party certificate published in the COA portal.
1 × Tesamorelin (2MG lyophilized vial). Lyophilized vial — reconstitute with bacteriostatic water before laboratory use.
Tesamorelin is a synthetic GHRH analog stimulating endogenous growth hormone secretion in research models. Studied for visceral fat reduction, lipodystrophy management, and metabolic modulation, this peptide supports IGF-1 regulation studies, body composition research, and age-related hormonal investigations. Elev8 Labs supplies Tesamorelin in 2mg lyophilized vials, HPLC verified for ≥98% purity, ensuring reproducible laboratory-grade consistency.
Tesamorelin is a synthetic GHRH analog stimulating endogenous growth hormone secretion in research models. Studied for visceral fat reduction, lipodystrophy management, and metabolic modulation, this peptide supports IGF-1 regulation studies, body composition research, and age-related hormonal investigations. Elev8 Labs supplies Tesamorelin in 2mg lyophilized vials, HPLC verified for ≥98% purity, ensuring reproducible laboratory-grade consistency.
As a recombinant GHRH receptor agonist, Tesamorelin binds pituitary GHRH receptors triggering pulsatile growth hormone release. Preclinical data demonstrate efficacy in reducing abdominal adiposity, improving insulin sensitivity, and modulating lipid metabolism. Research Use Only—not approved for human or veterinary use.
Tesamorelin (CAS 218949-48-5) is a 44-amino-acid synthetic GHRH analog replicating endogenous growth hormone-releasing hormone activity. Its molecular structure enhances receptor affinity and extends biological half-life compared to native GHRH peptides. Tesamorelin selectively activates GHRH receptors on somatotroph cells, initiating signaling cascades culminating in growth hormone release and IGF-1 production.
Laboratory studies show Tesamorelin stimulates growth hormone secretion through GHRH receptor activation, triggering hepatic IGF-1 synthesis and downstream effects including lipolysis, protein anabolism, and glucose modulation. Unlike exogenous GH administration, Tesamorelin preserves physiological feedback mechanisms. Animal models demonstrate tissue-specific visceral adipose reduction without proportional subcutaneous fat loss. Safety profiles indicate minimal disruption to cortisol, thyroid, or prolactin axes.
Tesamorelin peptide research encompasses multiple physiological systems and pathological models, with primary focus areas including:
Clinical trials demonstrate significant visceral adipose tissue reductions following Tesamorelin administration, with CT imaging revealing preferential trunk fat loss. Research examines mechanisms underlying selective lipolysis, including GH-mediated adipocyte signaling, beta-adrenergic receptor upregulation, and hormone-sensitive lipase activation.
Tesamorelin research elucidates GHRH receptor activation kinetics, GH secretion dynamics, and IGF-1 production patterns. Laboratory models assess pulsatile versus sustained GH release profiles, receptor desensitization mechanisms, and downstream anabolic effects. These investigations advance GH axis regulation understanding.
Aging research employs Tesamorelin to model growth hormone deficiency states. Studies examine correlations between declining GH secretion, increased visceral adiposity, reduced lean mass, and deteriorating metabolic markers. Data suggest potential for restoring body composition patterns through GHRH analog administration.
Metabolic protocols incorporate Tesamorelin for investigating glucose homeostasis, insulin sensitivity, and lipid modifications. Animal models demonstrate improved hepatic glucose metabolism, enhanced peripheral insulin action, and favorable alterations in triglyceride and HDL cholesterol levels.
Tesamorelin addresses HIV-associated lipodystrophy, characterized by excess visceral adiposity and peripheral fat loss. Clinical programs assess efficacy in reducing trunk fat accumulation while evaluating metabolic and cardiovascular parameters. These studies provide insights for broader lipodystrophy conditions.
Preclinical toxicology studies demonstrate favorable Tesamorelin safety profiles across multiple animal species, with no acute toxicity at therapeutic concentrations. Chronic administration reveals minimal effects on hypothalamic-pituitary-adrenal axis, thyroid homeostasis, or reproductive hormones.
Clinical trial data indicate generally well-tolerated profiles. Common observations include injection site reactions, arthralgia, peripheral edema, and transient hyperglycemia. Research protocols incorporate routine biomarker surveillance including fasting glucose, HbA1c, IGF-1, and hepatic enzymes.
Tesamorelin from Elev8 Labs is manufactured exclusively for Research Use Only with no FDA approval. This product must not be utilized in clinical treatment, human administration, veterinary medicine, or non-laboratory contexts. Researchers must operate within institutional guidelines and maintain proper laboratory safety protocols.
Store lyophilized Tesamorelin vials at -20°C protected from light and moisture. Reconstitute using sterile bacteriostatic water under aseptic technique, achieving 1-2mg/mL concentrations. Following reconstitution, store at 2-8°C and utilize within stability windows. Avoid repeated freeze-thaw cycles.
Each 2mg Tesamorelin vial arrives as sterile lyophilized powder requiring reconstitution. Standard protocols employ bacteriostatic water (0.9% benzyl alcohol), with volumes adjusted to achieve desired concentrations. Research models commonly utilize 0.5-2.0mg dosing based on species, body weight, and experimental endpoints.
The Elev8 Labs Calculator converts vial content, diluent volume, and target dosages into precise injection volumes, eliminating manual errors. This complimentary tool supports consistent peptide concentrations across experiments.
Visit our Peptide Dosage Calculator
Every Tesamorelin batch undergoes independent HPLC analysis by accredited laboratories, confirming ≥98% purity. Analytical certificates document molecular identity, quantify peptide content, and verify absence of significant impurities or degradation products.
Elev8 Labs implements pharmaceutical-grade manufacturing with validated synthesis protocols, sterile filtration, controlled lyophilization, and stringent quality testing. This delivers batch-to-batch consistency critical for longitudinal studies, multi-center collaborations, and publication-quality data.
Advanced lyophilization removes water while preserving peptide structure, extending shelf life and maintaining biological activity. Each vial undergoes terminal sterilization and hermetic sealing in Type I borosilicate glass, protecting against moisture, oxidation, and contamination.
Academic institutions, pharmaceutical companies, and independent laboratories worldwide rely on Elev8 Labs for critical peptide supplies supporting growth hormone research, metabolic studies, and translational programs. Our commitment to quality, regulatory compliance, and responsive service establishes us as a preferred supplier.
Tesamorelin research frequently incorporates complementary peptides targeting growth hormone pathways, metabolic regulation, and body composition modification. The following compounds offer synergistic or comparative value for comprehensive experimental protocols:
A long-acting GHRH analog with Drug Affinity Complex technology, CJC-1295 with DAC extends GH secretion through albumin binding and prolonged half-life. Researchers compare sustained GH elevation versus pulsatile patterns. 2mg vials, ≥98% purity.
The shorter-acting variant lacking DAC modification, CJC-1295 without DAC models natural GH pulse dynamics with 30-minute half-life. Protocols employ this for investigating physiological GH secretion patterns. 2mg vials, HPLC verified.
A selective GH secretagogue via ghrelin receptor pathways, Ipamorelin stimulates GH release through mechanisms distinct from GHRH agonism. Studies examine synergistic effects when combined with Tesamorelin. 2mg vials, ≥98% purity.
Comprising the active 1-29 amino acid fragment of human GHRH, Sermorelin represents native growth hormone-releasing hormone without synthetic modifications. Researchers utilize this as comparative standard when assessing Tesamorelin's enhanced potency. 2mg vials, HPLC verified.
Operating through GLP-1 receptor activation, Semaglutide complements Tesamorelin research by addressing metabolic syndrome components including appetite regulation, glucose homeostasis, and body weight. Comparative studies assess different mechanisms for body composition outcomes. 5mg vials, ≥98% purity.
Navigate to the Tesamorelin product page and specify required 2mg vial quantities. Volume discounts apply: 5-8 units receive 5% reduction, 9+ units qualify for 10% savings. Bulk options accommodate long-term protocols.
Click 'Add to Cart' and proceed to secure checkout. The streamlined system maintains confidentiality while capturing shipping and payment information. SSL encryption protects transmitted data.
We accept all major credit and debit cards — Visa, Mastercard, American Express and Discover — processed securely at checkout.S. payments. Credit and debit card processing available through Max Redemption gateway requiring one-time identity verification.
Provide accurate delivery address with proper laboratory facility designation. Free U.S. shipping applies to orders exceeding $100, international orders over $275 qualify for complimentary delivery. Express upgrades available.
Following payment confirmation, orders process within 2-4 business days. Standard fulfillment utilizes Priority Mail for U.S. destinations (1-7 days) and equivalent international carriers (10-15 days). Orders exceeding $150 require signature confirmation.
Upon dispatch, tracking numbers arrive via email enabling real-time monitoring. All shipments utilize discreet packaging without external product identification. Temperature-controlled packaging protects peptide integrity during transit.
Tesamorelin remains a cornerstone peptide for growth hormone research, lipodystrophy studies, and metabolic investigations. With HPLC-verified ≥98% purity, sterile lyophilized formulation, and global distribution, Elev8 Labs supports reproducible research from protocol development through publication. Every production step prioritizes quality, consistency, and regulatory compliance for authorized laboratory applications under Research Use Only designation.
⚠️ For Research Use Only – Not for human or veterinary use. Intended for laboratory, academic, and in-vitro research only.
Verified molecular and structural reference for laboratory research use.
| Compound name | Tesamorelin |
|---|---|
| CAS number | 218949-48-5 |
| Format | 2MG lyophilized vial |
| Research category | Metabolic Research · Growth Hormone Research |
| Testing laboratory | Chromate Analytical · independent third party |
Values are provided as published reference figures for research identification. Always confirm against the batch-specific Certificate of Analysis. For laboratory and research use only.
| Elev8 Labs | Typical supplier | |
|---|---|---|
| Per-batch third-party COA | ✓ Yes | Rarely provided |
| RP-HPLC purity testing | ✓ Yes | Inconsistent |
| Identity verified by independent lab | ✓ Yes | Often unverified |
| Cold-chain shipping | ✓ Yes | Rarely |
| Discreet, tracked packaging | ✓ Yes | Varies |
| Same-day dispatch | ✓ Yes | Varies |
Selected to match this product's preparation workflow and research category.
Long-Acting GHRH Analog • Drug Affinity Complex
Short-Acting GHRH Analog • Modified GRF (1-29)
Growth Hormone Releasing Peptide-2
Growth Hormone Releasing Hexapeptide